Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts
Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions.
Ardelyx Inc. (ARDX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 17,842,370 | $106,875,796 | +50% | 0.04% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 4,274,043 | $25,601,518 | +217% | 0.02% |
| 3. | Citadel Investment Group Ken Griffin | 3,464,774 | $20,753,997 | +162% | 0% |
| 4. | Point72 Asset Management Steve Cohen | 2,984,261 | $17,875,723 | +212% | 0.02% |
| 5. | AQR Capital Management Cliff Asness | 2,439,450 | $14,612,307 | +21% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.84 | 333,333 | $1,946,331.39 | 3,302,918 | 2026-02-20 | Filing | |
| $3.63 | 200,000 | $725,880.00 | 2,896,871 | 2025-06-16 | Filing | |
| $3.69 | 200,000 | $737,260.00 | 2,696,871 | 2025-06-09 | Filing | |
| $3.29 | 100,000 | $329,120.00 | 2,496,871 | 2025-05-15 | Filing | |
| $4.22 | 381,377 | $1,610,936.45 | 2,396,871 | 2025-05-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.06 | 41,668 | $210,923.42 | 1,678,366 | 2026-07-15 | Filing | |
| $5.99 | 81,898 | $490,487.12 | 378,195 | 2026-06-18 | Filing | |
| $5.67 | 41,666 | $236,346.22 | 1,699,200 | 2026-06-15 | Filing | |
| $6.27 | 1,036 | $6,493.13 | 149,836 | 2026-05-21 | Filing | |
| $6.27 | 2,683 | $16,815.70 | 149,107 | 2026-05-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,211,690 | $6,179,619 | 0.18% | |
| 2. | 290,254 | $1,480,295 | 0.03% | |
| 3. | 137,660 | $702,066 | 0.03% | |
| 4. | 116,369 | $593,482 | 0.05% | |
| 5. | 97,247 | $495,959 | 0.01% |
News See All
10 Best Low Priced Stocks to Get Rich in 2026
These days, everyone is focusing on finding ways to get rich. The real catch is when this opportunity comes at a low price.
Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot
According to a study by Alejandro Lopez-Lira and Yuehua Tang from the University of Florida, ChatGPT and other large language models can extract meaningful trading signals from financial news headlines...
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2026 Earnings Call Transcript
Operator: Welcome to the Ardelyx First Quarter 2026 Earnings Call. All participants will be in a listen-only mode.
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Ardelyx Fourth Quarter 2025 Earnings Conference.
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
10 Best Small-Cap Stocks Ready to Explode in 2026
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks.
Hedge Fund Resource Center